Literature DB >> 12145735

Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome.

Yoshimi Kikuchi1, Ikumi Genka, Azumi Ishizaki, Keishin Sunagawa, Akira Yasuoka, Shinichi Oka.   

Abstract

We describe 2 patients with acquired immunodeficiency syndrome who had potentially fatal bradyarrhythmia that occurred shortly after commencement of antiretroviral therapy. Lopinavir-ritonavir was the only drug that both patients were using.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145735     DOI: 10.1086/341975

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  4 in total

Review 1.  Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.

Authors:  Paola Magro; Isabella Zanella; Marta Pescarolo; Francesco Castelli; Eugenia Quiros-Roldan
Journal:  Biomed J       Date:  2020-11-10       Impact factor: 4.910

2.  Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.

Authors:  Zheng Zequn; W U Yujia; Q I A N Dingding; L I A N Jiangfang
Journal:  Eur J Pharmacol       Date:  2020-12-17       Impact factor: 4.432

Review 3.  Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Authors:  Risto S Cvetkovic; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

4.  COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.

Authors:  Laureen Yi-Ting Wang; Gavin Yeow Ping Ng
Journal:  Eur Heart J Case Rep       Date:  2020-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.